INTRODUCTION
Infertility is defined as the failure to achieve a pregnancy within one year of regular (at least three times per month) unprotected intercourse. It affects DSSUR[LPDWHO\ RI VH[XDOO\ DFWLYH FRXSOHV D FDXVDWLYH PDOH IDFWRU LV SUHVHQW LQ DSSUR[LPDWHO\ 40% of cases. [1] Infertility is regarded as 'male factor' when an alteration in sperm concentration and/or motility and/or morphology is present in at least one sample of two sperm analyses, which comply with the World Health Organization (WHO) 1999 guidelines, collected between one to four weeks apart. [2] Male infertility may be characterized by oligoasthenoteratozoospermialow sperm count with a high percentage of slow-moving DQG DEQRUPDO VHPHQ $SSUR[LPDWHO\ RI FDVHV DUH considered idiopathic, meaning that no cause can be found with common clinical, instrumental or laboratory methods. Treating idiopathic oligoasthenoteratozoospermia (iOAT) can be problematic--although a variety of drugs and dietary supplements are available, many are prescribed without any UDWLRQDOH DQG ZLWKRXW DQ\ HYLGHQFH VXSSRUWLQJ WKHLU HI¿FDF\ In addition, although assisted reproductive techniques have been proposed as a possible solution for male factor LQIHUWLOLW\ LQ JHQHUDO WKH\ DUH H[SHQVLYH QRW XQLYHUVDOO\ available, and have limited success.
This review article will discuss the causes of iOAT, the role SOD\HG E\ R[LGDWLYH VWUHVV LQ LPSDLULQJ VSHUPDWRJHQHVLV DQG the current knowledge regarding pharmacotherapy in the medical management of this condition.
IDIOPATHIC OLIGOASTHENOTERATOZOOSPERMIA
Idiopathic oligoasthenoteratozoospermia is related to defective spermatogenesis, the origin of which is unknown and often regarded as undetectable by common laboratory methods. This condition is characterized by necrosis and apoptosis of gametes (oligoteratozoospermia), reduction in the percentage of normal sperm forms, and impairment of sperm motility (asthenospermia). [3] In addition to sperm DQDO\VLV ¿QGLQJV WKHUH PD\ EH D KLVWRORJLFDO SLFWXUH RI PL[HG DWURSK\ RI WKH WHVWLFOHV ZLWK QRUPDO VHUXP OHYHOV of testosterone, follicle-stimulating hormone (FSH) DQG OXWHLQL]LQJ KRUPRQH /+ L2$7 FDQ EH FODVVL¿HG as: isolated astheno ± teratospermia (no alteration in semen concentration); moderate (sperm concentration <20×10 6 / mL and >5×10 6 /mL); or severe (sperm concentration <5×10 6 mL). [3] A large number of iOAT infertile patients have a normal SK\VLFDO H[DPLQDWLRQ QRUPDO KRUPRQDO SUR¿OH DQG QR discernable cause of their subfertile status. [4, 5] Although hormonal abnormalities are not always evident, iOAT is sometimes associated with lower serum testosterone and inhibin levels and higher serum estradiol, LH and FSH levels. [6, 7] These changes may also be age-related as semen volume and sperm motility are seen to continuously decrease from 22 to 80 years of age, while sperm concentration is not affected. [8] 1RQLQÀDPPDWRU\ IXQFWLRQDO DOWHUDWLRQV in post-testicular organs such as the epididymis may be implicated in iOAT by altering the DNA methylation of gametes. [9] Methylation mediates transcriptional repression by recruiting histone deacetylase. Genes must undergo demethylation in order for gene transcription to occur. [10] $V\PSWRPDWLF LQIHFWLRQV ZLWKRXW VLJQL¿FDQW OHXNRVSHUPLD due to herpes virus, adeno-associated virus and Chlamydia trachomatis (CT), have been linked to iOAT. [11, 12] The prevalence of asymptomatic CT has been estimated at 20% in men with iOAT. [13, 14] As this percentage is higher than in the control population, asymptomatic CT infection has been regarded by some as a cause of iOAT. However, other researchers have found the CT prevalence (of DSSUR[LPDWHO\ WR EH VLPLODU DPRQJ L2$7 DQG IHUWLOH subjects. [15] In general, male infertility appears to have a familial occurrence, especially among brothers and maternal uncles, who often have normal blood levels of FSH and LH. [16] An autosomal recessive mode of inheritance has been suggested. [17] A genetic etiology is currently considered the most acceptable theory.
THE ROLE OF OXIDATIVE STRESS IN IDIOPATHIC OLIGOASTHENOTERATOZOOSPERMIA
5HDFWLYH R[\JHQ VSHFLHV 526 DUH PROHFXOHV WKDW KDYH at least one unpaired electron, rendering them highly unstable and highly reactive in the presence of lipids, amino acids and nucleic acids. [18] At physiologic levels, ROS are essential for normal reproductive function, acting as metabolic intermediates in the metabolism of prostanoid, in the regulation of vascular tone, in gene regulation, and in facilitated sperm capacitation and acrosome reaction. +RZHYHU DW KLJKHU FRQFHQWUDWLRQV WKH\ H[HUW QHJDWLYH effects. [18] The main source of ROS production in seminal plasma is leukocytes and immature spermatozoa. Spermatids and mature spermatozoa are deemed highly sensitive to ROS because their membranes are particularly rich in polyunsaturated lipids. [19] It is not known at which point WKH SHUR[LGDWLYH GDPDJH WR VSHUPDWR]RD RFFXUV ZKHWKHU within semen (during the time required for liquefaction), in the epididymis (where spermatozoa are stored before ejaculation), or in the testis. By altering membrane integrity, ROS may impair sperm motility and morphology and can lead to sperm cell death. [20] 7KH [22] [23] [24] [25] The concentration of PDORQGLDOGHK\GH 0'$ D PDUNHU RI OLSLG SHUR [ LGDWLRQ was found to be almost twice as high in sperm pellet suspensions of asthenospermic and oligoasthenospermic patients compared to normospermic males. [24] Kobayashi demonstrated that the in vitro DGGLWLRQ RI H[RJHQRXV 62' WR semen samples led to improved sperm motility and a decrease in MDA concentration. [26] =LQF GH¿FLHQF\ ZDV VHHQ WR FRQIHU YXOQHUDELOLW\ WR R[LGDWLYH VWUHVV in vitro, leading to increased sperm DNA fragmentation and apoptosis. [27] Intracellular zinc modulates the levels of pro-apoptotic p53, p21 and bcl 2 IDPLO\ JHQH H[SUHVVLRQ DQG FDVSDVH DFWLYLW\ %FO KDV D UROH in regulating programmed cell death by functioning as an DQWLR [ LGDQW DW WKH RXWHU PHPEUDQH RI WKH PLWRFKRQGULD [28, 29] In a study by Omu et [27] Apoptosis and markers of programmed cell death are inversely correlated with sperm motility, [30] morphology, vitality and concentration. [30, 31] 'HFUHDVHG H[SUHVVLRQ RI VXUYLYLQ a programmed cell death inhibitor, has been correlated with increased severity of iOAT. However, it should be noted that increased apoptosis is implicated in several types of OAT, including that associated with hormonal infertilities, [32] anti-sperm antibody-associated infertility, varicocele, testicular torsion [33] and inflammation. [34] Therefore, accentuated programmed cell death is not pathognomonic for iOAT. Several studies have shown that, in addition to an increased susceptibility to apoptosis and DNA fragmentation, spermatozoa from OAT patients RIWHQ H[KLELW FKURPRVRPDO DQHXSORLG\ DQG PLWRFKRQGULDO dysfunction. [35] 0LWRFKRQGULDO '1$ R [ LGDWLYH GDPDJH KDV been observed in asthenospermic infertile men [36] and FRQ¿UPHG LQ H[SHULPHQWDO PRGHOV [37] These alterations are YHU\ VLPLODU WR WKH PLWRFKRQGULDO PRGL¿FDWLRQV VHHQ LQ apoptotic sperm cells. [38] [39] [40] [41] 
ANTIOXIDANT TREATMENT OF IOAT
Medical treatment for male infertility can often be a frustrating problem because it is a multifactorial disorder IRU ZKLFK DQ LGHQWL¿DEOH FDXVH FDQQRW EH IRXQG LQ WKH YDVW majority. [3] Unlike with genetic factors, nutritional factors can be changed by altering the patient's diet. Pharmacotherapy for iOAT consists of oral supplementation with hormones DQG DQWLR[LGDQWV ZLWK WKH DLP WR LPSURYH DQG PDLQWDLQ semen parameters. Increased sperm concentration in men with OAT has been associated with a disproportionately higher fecundability. [42] Treatments that improve sperm concentration will result in stronger probability of conception when the initial sperm count is low, rather than high. [43] [45] Men with iOAT are likely to be prescribed a number of HPSLULFDO WKHUDSLHV +RZHYHU WKH VFLHQWL¿FDOO\ DFFHSWDEOH HYLGHQFH VKRZLQJ WKHLU EHQH¿W LQ FRQWUROOHG KXPDQ VWXGLHV is sparse. In the absence of approved and effective medical treatment for iOAT, certain medications continue to be prescribed based purely on their rationale and the fact WKDW WKH\ ODFN VLJQL¿FDQW VLGHHIIHFWV 7R GH¿QH D GUXJ DV active, it should improve sperm parameters and pregnancy rates in at least one blind, prospective, placebo-controlled trial; more of these trials from independent groups are needed in order to define a drug as unquestionably active. [46] The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) working group KDV GHYHORSHG D V\VWHPDWLF DQG H[SOLFLW DSSURDFK WR making judgments regarding the quality of evidence and strength of recommendations. [47] A scoring system based on this framework [48] was used by us to evaluate each pharmacotherapeutic agent based on the current available evidence regarding its effectiveness in the treatment of iOAT. (YLGHQFH ZDV HYDOXDWHG DFURVV VWXGLHV IRU VSHFL¿F FOLQLFDO RXWFRPHV WDNLQJ LQWR DFFRXQW WKH PHWKRGRORJLFDO ÀDZV within the component studies, the consistency of results across different studies, how generalizable the research results are to the wider patient base, and how effective the treatments have been shown to be. All treatment FRPSDULVRQV ZHUH JLYHQ RQH RI IRXU *5$'( VFRUHV UHÀHFWLQJ the quality of the evidence: high, moderate, low or very low [ Table 1 ]. We believe this approach may give clinicians a clear view of the evidence relating to key treatment interventions.
HORMONE PHARMACOTHERAPY
The reproductive tract microenvironment of men with L2$7 KDV EHHQ HVWDEOLVKHG DV DQGURJHQGH¿FLHQW $QGURJHQ dependent epididymal and accessory gland function [49] may be boosted by androgen stimulation. [50] 7DPR[LIHQ ZDV ¿UVW LQWURGXFHG DV DQ HPSLULFDO WUHDWPHQW [51] as it acts on hypothalamic receptor sites to stimulate gonadotropin release. [52] Furthermore, it affects Leydig cell function to increase tubular and epididymal 5a-dihydrotestosterone. Willis [55] 7HVWRVWHURQH XQGHFDQRDWH DGPLQLVWUDWLRQ H[HUWV LWV DFWLRQV mainly on epididymal function, improving sperm motility, morphology and fertilization capacity. [55] [56] [57] Androgens are given as a safeguard against possible disturbances of synthesis, metabolism and binding of these steroids, which is often implicated in the infertility associated with iOAT. [58] [59] [60] Adamopoulos et al. conducted a randomized control trial and found that this combined regimen produced a satisfactory improvement in total sperm number, motility and functional VSHUP IUDFWLRQ DIWHU WKUHH DQG VL[ PRQWKV [50] Folliclestimulating hormone (FSH) has been shown to stimulate spermatogenesis in an animal model. Administration of a high dose of FSH was seen to be particularly promising for improving disturbed sperm structure. [61, 62] Based on this, various attempts have been made to increase sperm production in patients with OAT by administering FSH, but the results are still controversial. The subjects of an uncontrolled study by Ben-Rafael et al., demonstrated both an increased pregnancy rate and improved classical semen parameters, [63] whereas other uncontrolled studies have shown only improved semen parameters. [64] [65] [66] Randomized controlled trials by Kamische et al., and Foresta et al., failed to demonstrate improvement in sperm parameters or pregnancy rates. However, testicular volume and DNA condensation increased, which suggests a potential role for FSH in the treatment of iOAT. Another randomized controlled trial by Baccetti et al., reported that FSH therapy OHG WR D VLJQL¿FDQW LPSURYHPHQW LQ VSHUP XOWUDVWUXFWXUH DQG increased probability of embryo implantation, as evidenced by higher pregnancy rates in the partners of the treated patients. [67] However, as patients with iOAT are a highly heterogeneous group, not all patients are likely to respond to hormone therapy.
CARNITINES &DUQLWLQH LV D ZDWHUVROXEOH DQWLR[LGDQW PRVWO\ GHULYHG IURP WKH KXPDQ GLHW DSSUR[LPDWHO\ LV V\QWKHVL]HG IURP O\VLQH DQG PHWKLRQLQH ([WUDFHOOXODU DQG LQWUDFHOOXODU
carnitine may play a role in sperm energy metabolism, providing the primary fuel for sperm motility via post- [68] Carnitines accumulate in the epididymis in both free and acetylated forms and are used by spermatozoa for mitochondrial bR[LGDWLRQ of long chain fatty acids, this being the principal shuttle and transfer system of the acyl to the mitochondrial CoA. [69, 70] Carnitines enhance the cellular energetics in mitochondria by facilitating the entry and utilization of free fatty acids within the mitochondria and also restore the phospholipid composition of mitochondrial membranes by decreasing IDWW\ DFLG R[LGDWLRQ [71] [72] [73] Carnitine protects sperm DNA and cell membranes from free radical-induced damage and apoptosis [72, 74, 75, 76] and has been correlated with sperm parameters such as concentration and motility, which relate to higher fecundity. [77, 78] The initiation of sperm motility is thought to occur in parallel to an increase in carnitine concentration in the epididymal lumen and L-acetylcarnitine in spermatozoa. [68, 79, 80] The degree of acetylation of carnitine was shown to be greater in motile than in immotile spermatozoa. [81] 7KLV LV VLJQL¿HG E\ WKH IDFW WKDW SDWLHQWV ZLWK defective sperm motion parameters were shown to have a reduced L-acetyl-carnitine/L-carnitine ratio. [82] The results of preliminary, uncontrolled studies [83] [84] [85] suggest that oral carnitine supplementation has a favorable effect on sperm motion characteristics of men with iOAT. A daily carnitine dose of 3 g given for four months [83] or for three months [84] ZDV VHHQ WR VLJQL¿FDQWO\ LPSURYH SDWLHQWV ¶ VSHUP motility from baseline (pretreatment) levels. A higher dose of 4 g per day over a shorter treatment duration (two months) increased progressive sperm motility in 15 of 20 patients. This effect was more pronounced in seven patients whose partners achieved pregnancy during treatment and followup. The utility of carnitine to improve sperm motility of patients with iOAT is supported by more recent, randomized controlled trials in which 2 g carnitine was administered daily. [72, 74, 75] 7KH PRVW VLJQL¿FDQW LPSURYHPHQW LQ PRWLOLW\ was seen in the groups with lower baseline motility. [72, 74] Therefore, carnitine's action may differ depending on the pretreatment semen characteristics. Studies conducted by Lenzi et al., failed to demonstrate any improvement in morphology. [72, 74] which suggests that carnitine's effects are post-testicular. Conversely, Cavallini et al., reported LPSURYHG PRUSKRORJ\ DW WKUHH DQG VL[ PRQWKV LQ WKH FRXUVH of therapy. [75] In all of the studies, there was no further LPSURYHPHQW LQ VSHUP SDUDPHWHUV DW WKUHH DQG VL[ PRQWKV demonstrating that the treatment effects were stable.
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
The tubuloseminal plasma of OAT patients has been shown WR H[KLELW HOHYDWHG OHYHOV RI SURVWDJODQGLQ [86, 87] Treatment with low-dose NSAIDs was shown to improve sperm quality and fertility in an animal model. [88] Interestingly, carnitine administration was reported to promote the accumulation of prostaglandin E2 in seminal fluid. [89] Therefore, the concomitant administration of NSAIDs with carnitines may have a complementary mechanism that facilitates the positive effects of carnitine therapy while counteracting H[FHVV SURVWDJODQGLQ SURGXFWLRQ +RZHYHU D FHUWDLQ OHYHO RI SURVWDJODQGLQV DQG R[LGDWLYH VWUHVV LV UHTXLUHG for physiologic sperm functioning. Although long-term treatment with NSAIDs at low doses has been associated with improved sperm quality and fertility, [88] in vitro H[SHULPHQWV KDYH LOOXVWUDWHG WKDW KLJKHU GRVDJH RI 16$,'V may inhibit sperm motility. [90] NSAIDs administered via a VXSSRVLWRU\ DUH WKRXJKW WR H[HUW D PRUH SURQRXQFHG DQG direct effect on seminal plasma due to rectal-prostatic lymphatic pathways. [91] A 30 mg suppository of the NSAID &LQQR[LFDP FRPELQHG ZLWK RUDO /FDUQLWLQH DQG DFHW\O /FDUQLWLQH VLJQL¿FDQWO\ LQFUHDVHG VSHUP FRQFHQWUDWLRQ motility and morphology and pregnancy rates compared to placebo and to the two forms of carnitines alone. [75] 7KH FRPELQDWLRQ RI FLQQR[LFDP DQG FDUQLWLQH ZDV SURYHQ WR EH VLJQL¿FDQWO\ PRUH DFWLYH WKDQ SODFHER LQ WZR EOLQG prospective controlled trials, and thus, this drug combination is likely to be considered effective.
VITAMIN C AND E

Vitamin E (a-tocopherol) is one of the most important OLSLGVROXEOH DQWLR[LGDQW PROHFXOHV UHVLGLQJ PDLQO\ in the cell membranes. It is thought to interrupt the FKDLQ UHDFWLRQV LQYROYLQJ OLSLG SHUR[LGDWLRQ DQG HQKDQFH WKH DFWLYLW\ RI YDULRXV DQWLR[LGDQWV WKDW VFDYHQJH IUHH radicals generated during the univalent reduction of PROHFXODU R[\JHQ DQG GXULQJ QRUPDO DFWLYLW\ RI R[
LGDWLYH enzymes. [92, 93] Vitamin E acts by breaking pathological, 526LQGXFHG FKDLQ UHDFWLRQV 7KHUHIRUH WKLV DQWLR[LGDQW confers its protective effects by shielding sperm membrane FRPSRQHQWV IURP 26 GDPDJH UDWKHU WKDQ E\ LQÀXHQFLQJ 526 SURGXFWLRQ LWVHOI 9LWDPLQ ( KDV EHHQ XVHG H[WHQVLYHO\ in vivo to treat a variety of diseases.
[
94] The results of in vitro H[SHULPHQWV VXJJHVW WKDW YLWDPLQ ( PD\ SURWHFW VSHUPDWR]RD IURP R[
LGDWLYH GDPDJH DQG ORVV RI PRWLOLW\ as well as enhance the sperm performance in the hamster egg penetration assay. [95] In contrast to an earlier study by Giovenco et [24, 96] 2UDO YLWDPLQ ( VLJQL¿FDQWO\ GHFUHDVHG VSHUPDWR]RDO 0'$ concentration and increased motility. Vitamin E treatment greatly decreased the MDA concentration in spermatozoa down to normospermic levels, and this change in levels seemed to be a good predictor of pregnancy in the patients' spouses. [24] Vitamin C (ascorbic acid) is a water-soluble ROS scavenger with high potency. It is found in concentrations 10fold higher in seminal plasma than in serum. [97, 98] Ascorbic acid protects human spermatozoa against endogenous R[LGDWLYH '1$ GDPDJH [99] 6LJQL¿FDQWO\ UHGXFHG DVFRUEDWH concentrations have been observed in poor semen samples ULGGOHG ZLWK H[FHVV 526 [100] Seminal plasma ascorbic acid concentrations have been positively correlated with percentage of morphologically normal spermatozoa. [101] Therefore, vitamin C supplementation has been assessed for its potential as an oral supplement, along with vitamin E, in the treatment of idiopathic male infertility. The combined hydrophilicity and lipophilicity of vitamins C and E has been hypothesized to act synergistically in vivo to reduce SHUR[LGDWLYH DWWDFN RQ VSHUPDWR]RD [102] A randomized controlled double-blind study by Rolf et al., showed that high-dose oral treatment with vitamin C and E for 56 days did not improve semen parameters, sperm survival or pregnancy rates in iOAT. [103] Although studies have not demonstrated vitamin E and C to be effective, [96, [103] [104] [105] prospective controlled clinical studies should be carried out XVLQJ VHOHFWHG SDWLHQWV ZLWK LGHQWL¿HG DQG NQRZQ '1$ GDPDJH IRU ZKRP DQWLR[LGDQW WUHDWPHQW PD\ EH HIIHFWLYH SELENIUM Selenium (Se) is an essential element for normal testicular development, spermatogenesis, and spermatozoa motility and function. [106] 
al., in which patients failed to show any EHQH¿W IURP YLWDPLQ ( UHFHQW UDQGRPL]HG FRQWURO WULDOV KDYH UHSRUWHG YLWDPLQ ( VXSSOHPHQWDWLRQ WR EH HI¿FDFLRXV LQ WUHDWLQJ LQIHUWLOLW\ LQ PDOHV ZLWK R[LGDWLYH VWUHVV
6H PD\ SURWHFW DJDLQVW R[LGDWLYH '1$ GDPDJH LQ KXPDQ VSHUP FHOOV +RZHYHU WKH H[DFW PHFKDQLVP E\ ZKLFK 6H HOLPLQDWHV R[
LGDWLYH VWUHVV WR improve male fertility and semen quality in humans is still controversial. The role of Se could be mediated via VHOHQRHQ]\PHV VXFK DV SKRVSKROLSLG K\GURSHUR[LGH JOXWDWKLRQH SHUR[LGDVH 3+*3; [107] and the sperm capsular VHOHQRSURWHLQ JOXWDWKLRQH SHUR[LGDVH [108] There are at least 25 selenoproteins in the human body, and they help maintain sperm structure integrity. [106, 109] The best-characterized VSHUPDWR]RDO HIIHFWV RI 6H GH¿FLHQF\ DUH LPSRUWDQW ORVV RI motility, breakage at the midpiece level [110, 111] and increased incidence of sperm-shape abnormalities, mostly of the sperm head. [112] This is evidenced by studies that reported a significant correlation between Se levels in seminal plasma and the percentage of morphologically normal sperm in a sample. [113] 2WKHU VWXGLHV REVHUYHG D VLJQL¿FDQW positive correlation levels between sperm concentration and seminal plasma Se in patients consulting for infertility. [114, 115] However, such relationships between Se levels in semen or seminal plasma and sperm concentration or motility were not observed by other investigators. [116, 117] The effectiveness of combined treatment with selenium and vitamin E in treatment of iOAT has been studied since Vitamin E is well known to work in synergy with VHOHQLXP DV DQ DQWLSHUR[LGDQW [118, 119] A prospective, uncontrolled study reported that this drug combination OHG WR VWDWLVWLFDOO\ VLJQL¿FDQW LQFUHDVHV LQ PRWLOLW\ DQG PHDQ VHPLQDO SODVPD JOXWDWKLRQH SHUR[LGDVH DFWLYLW\ $OWKRXJK QR improvements in sperm concentration were documented, and no pregnancies were achieved, the better sperm motion FKDUDFWHULVWLFV PD\ EH H[SODLQHG E\ WKH DPSOL¿HG DQWLR[LGDQW enzyme activity. [120] 7KHVH UHVXOWV ZHUH IXUWKHU FRQ¿UPHG by a more recent randomized controlled trial in which vitamin E and selenium improved sperm motility and lipid SHUR[LGDWLRQ PDUNHUV [121] N-ACETYL CYSTEINE N-acetyl cysteine (NAC) is a derivative of the naturally-RFFXUULQJ DPLQR DFLG /F\VWHLQH DQG LW H[KLELWV DQWLR[LGDQW properties. As it is a precursor of glutathione (GSH), NAC works to increase the concentration of this endogenous reducing agent while also directly alleviating OS by scavenging free radicals. [122] 7KH DQWLR[LGDQW DFWLRQV RI 1$& have been observed to play an important role in germ cell survival in human seminiferous tubules in vitro. [123] Oeda et al., found that incubating semen samples with NAC for 20 PLQ VLJQL¿FDQWO\ GHFUHDVHG 526 OHYHOV DQG OHG WR LPSURYHG sperm motility. [124] An uncontrolled study by Comhaire et al., found that NAC improved sperm concentration and DFURVRPH UHDFWLRQ ZKLOH UHGXFLQJ 526 DQG R[LGDWLRQ RI sperm DNA. However, NAC did not appear to have an effect on motility and morphology. [125] 5HVHDUFKHUV KDYH VWXGLHG WKH HI¿FDF\ RI 1$& DV SDUW RI D FRPELQHG DQWLR[LGDQW UHJLPHQ $ UDQGRPL]HG FRQWUROOHG trial by Safarinejad et al., reported that NAC with selenium KDV DGGLWLYH EHQH¿FLDO HIIHFWV RQ PHDQ VSHUP FRQFHQWUDWLRQ and percent normal morphology. By the end of a 26-week WUHDWPHQW SHULRG PRWLOLW\ LQFUHDVHG VLJQL¿FDQWO\ LQ WKH combined treatment group and in those patients receiving selenium alone, compared to placebo. Furthermore, FRPELQDWLRQ WUHDWPHQW OHG WR VLJQL¿FDQWO\ EHWWHU VSHUP parameters than treatment with only selenium. [126] ZINC AND FOLIC ACID =LQF WKHUDS\ PD\ UHGXFH L2$7 E\ SUHYHQWLQJ R[LGDWLYH stress, apoptosis and sperm DNA fragmentation. Seminal plasma zinc concentrations have been demonstrated to GLIIHU VLJQL¿FDQWO\ EHWZHHQ IHUWLOH DQG VXEIHUWLOH PHQ [127] Zinc may promote male fertility by conferring protection WR VSHUP VWUXFWXUH =LQF GH¿FLHQF\ KDV EHHQ DVVRFLDWHG ZLWK JURVVO\ DEQRUPDO ÀDJHOOD VKRZLQJ PDUNHG K\SHUWURSK\ DQG K\SHUSODVLD RI WKH ¿EURXV VKHDWK D[RQHPDO GLVUXSWLRQ DQG partial defects of the inner dynein arms of microtubular GRXEOHWV ZLWK GLVWRUWHG LQQHU D[RQHPDO VWUXFWXUH DQG D poorly formed or absent midpiece. [27] Prospective studies show an improvement of sperm concentration, [128] [129] [130] progressive motility, sperm integrity and pregnancy rates in subfertile iOAT patients after zinc supplementation. In a recent randomized controlled trial by Omu et [27] Therefore, zinc may be useful in L2$7 LQ UHGXFLQJ R[LGDWLYH VWUHVV DQG WKH DVVRFLDWHG VSHUP membrane and DNA damage.
Zinc and folic acid are both essential for transfer RNA and DNA synthesis. However, the underlying mechanisms by which these micronutrients may affect spermatogenesis are not known. [131] According to the results of a study where this combined regimen led to an increase in sperm concentration, zinc and folic acid treatment were seen to have an endocrine-independent mechanism as FSH, testosterone and inhibin levels remained unaltered. [132] However, other studies have failed to demonstrate any VLJQL¿FDQW GLIIHUHQFH LQ FRQFHQWUDWLRQV RI ]LQF DQG IROLF acid between fertile and subfertile males. [133, 134] Landau et al., reported that daily supplementation with 10 mg of folic acid IRU GD\V KDG QR EHQH¿FLDO HIIHFW RQ VSHUP FRQFHQWUDWLRQ in normospermic or iOAT men. [135] Animal in vivo and in vitro VWXGLHV KDYH VKRZQ WKDW ]LQF GH¿FLHQF\ DOWHUV WKH absorption and metabolism of dietary folate. [136] [137] [138] A recent double-blind randomized controlled trial was conducted to assess whether zinc and folate supplementation work synergistically to improve semen quality. [139] Folic acid was given at a daily dose of 5 mg, and zinc sulfate was given at a daily dose of 66 mg. Subfertile men demonstrated D VLJQL¿FDQW LQFUHDVH LQ WRWDO QRUPDO VSHUP FRXQW and a minor increase of 4% in abnormal spermatozoa. A similar trend was observed in fertile men. However, whether the improvement in sperm concentration observed after administration of folic acid and zinc will lead to an increase in pregnancy rates remains to be established. Before widescale implementation of combined zinc and folic acid administration, we recommend that a larger randomized, SODFHERFRQWUROOHG VWXG\ RQ WKH HI¿FDF\ DQG VDIHW\ RI WKHVH compounds be done.
MAST CELL STABILIZERS
Maseki et al ¿UVW UHSRUWHG PDVWRF\WRVLV LQ WKH WHVWHV of infertile males, indicating that there is a relationship between mast cell proliferation and testicular dysfunction. [140] Testicular biopsy samples show that mast cell counts are higher in men with idiopathic infertility than in normospermic men. [141, 142] Hashimoto et al., demonstrated that the number of mast cells was increased not only in the interstitium but also in the lamina propria of the seminiferous tubules in the idiopathic infertile testes. [143] The administration of a mast cell blocking agent was reported to have positive effects on the semen parameters of infertile men in a pilot study. [144] Mast cell blocking agents inhibit the production or release of KLVWDPLQH OLSLG PHGLDWRUV DQG F\WRNLQHV IURP LQÀDPPDWRU\ cells and macrophages. These anti-inflammatory and LPPXQRPRGXODWRU\ SURSHUWLHV VHUYH WR GHFUHDVH R[LGDWLYH stress by suppressing the production of prostaglandins and LQWHUOHXNLQV DQG DWWHQXDWLQJ WKH SURLQÀDPPDWRU\ DFWLYLW\ of monocytes. Administration of the mast cell stabilizer, tranilast, has been reported to lead to the appearance of VSHUPDWR]RD LQ WKH VHPLQDO ÀXLG RI PHQ ZLWK LGLRSDWKLF azoospermia within a year of treatment. [145] Yamamoto et al., conducted a controlled, single-blind study LQ ZKLFK WUDQLODVW VLJQL¿FDQWO\ LQFUHDVHG WKH SUHJQDQF\ rate from 0% in the placebo group to 26.8% in men with idiopathic severe oligozoospermia treated with 200 mg of tranilast per day for three months. The mast cell blocker JURXS H[KLELWHG VLJQL¿FDQWO\ KLJKHU OHYHOV RI VSHUP GHQVLW\ sperm motility, and total motile sperm count. However, the two groups did not differ in terms of seminal volume and normal sperm morphology. [146] Hibi et al., performed D GRXEOHEOLQG FRQWUROOHG VWXG\ WR FRQ¿UP WKHVH ¿QGLQJV using the same dosage and duration of tranilast treatment LQ PHQ ZLWK L2$7 7UHDWPHQW UHVXOWHG LQ VLJQL¿FDQWO\ increased sperm concentration, although there was no change in motility, morphology or pregnancy rates when compared to placebo. Another study by Hibi et al. further FRQ¿UPHG WKDW WUDQLODVW GHPRQVWUDWHV D FHUWDLQ FOLQLFDO benefit in iOAT. However, this improvement was not sustained after discontinuation of therapy. [147] 
LYCOPENE
Lycopene is a naturally synthesized carotenoid found in fruits and vegetables and is an important component of WKH KXPDQ UHGR[ GHIHQVH PHFKDQLVP DJDLQVW IUHH UDGLFDOV It has been found to have the highest physical quenching UDWH FRQVWDQW ZLWK VLQJOHW R[\JHQ DQG LWV SODVPD OHYHO LV higher than that of beta carotene. [148] Lycopene is found in high concentrations in the testes and seminal plasma. Levels tend to be lower in men suffering from infertility. Gupta and Kumar [149] [150, 151] and to preserve sperm motility in vitro [152] and improve semen parameters in vivo. [153, 154] Tesarik et al., demonstrated that in unselected asthenospermic patients, SHQWR[LI\OOLQH LPSURYHG VSHUP PRWLRQ FKDUDFWHULVWLFV VXFK as curvilinear velocity, path velocity and beat cross frequency but did not increase the percentage of motile spermatozoa. [155] Okada et al., studied the effects of in vitro and in vivo SHQWR[LI\OOLQH WUHDWPHQW RQ VSHUP PRWLRQ SDUDPHWHUV LQ select asthenospermic patients whose spermatozoa produced detectable steady state levels of ROS. Treatment decreased ROS formation and preserved sperm motion parameters in vitro 2UDOO\ DGPLQLVWHUHG SHQWR[LI\OOLQH KDG QR HIIHFW DW a low dosage, whereas a high dosage was seen to increase sperm motility and some sperm motion parameters without altering sperm fertilizing ability.
ADRENERGIC ANTAGONISTS
Although there is no clear pathophysiological basis for the use of a-blocking agents, they have been studied for their effects in the treatment of iOAT. [156] Two placebocontrolled trials demonstrated an improvement in sperm concentration but not of ejaculate volume, morphology, motility or pregnancy rates in the treatment group. [157, 158] 
CONCLUSION
Various methods of assisted reproduction have been proposed as a possible solution for male factor infertility. $OWKRXJK WKHVH WHFKQLTXHV KDYH PRWLYDWHG H[WHQVLYH research in sperm function, they have also hindered the development of new strategies for male factor infertility therapy. Assisted reproductive technology is not universally DYDLODEOH LV H[SHQVLYH DQG KDV OLPLWHG VXFFHVV 7KHUHIRUH DQ\ pharmacological agent that has a low cost and satisfactory HIIHFWLYHQHVV VKRXOG EH FRQVLGHUHG DV ¿UVWOLQH WUHDWPHQW in iOAT.
The pharmacological treatment of iOAT has yet to be standardized. Unfortunately, many drugs are currently used without any rationale: such therapies are often SUHVFULEHG VHTXHQWLDOO\ ZLWKRXW DQ\ EHQH¿FLDO HIIHFW DQG any improvements that do occur in semen parameters may be due to other unrelated reasons. Seasonal. [159] regional, [160] and racial [161] differences in sperm count and quality make it difficult to consider iOAT data as absolutely valid. Furthermore, the available forms of treatment have mostly produced only marginally satisfactory responses, even in the best of proper trials. This inadequacy relates to the fact that iOAT is a syndrome that has a number of different etiologies, and only some subsets will respond favorably to treatment, ZKHUHDV RWKHUV ZLOO H[SHULHQFH QR DSSUHFLDEOH FKDQJHV Routine laboratory investigation and semen analyses are unable to delineate iOAT subgroups according to etiology. )XUWKHUPRUH FRQÀLFWLQJ UHVXOWV DQG FRQFOXVLRQV LQ SXEOLVKHG studies could also arise from differences in the methodology of study design and semen analysis, andrological history and demographic characteristics of the study population. We sought to overcome this issue by employing a scoring system that allowed us to rank the quality of the overall HYLGHQFH DYDLODEOH RQ YDULRXV DQWLR[LGDQW WKHUDSLHV IRU iOAT. Future randomized controlled trials are needed with larger sample sizes and with selection criteria to identify and study different iOAT subgroups.
